269 related articles for article (PubMed ID: 27645786)
21. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
Rahman R; Goyal V; Haque R; Jamil K; Faiz A; Samad R; Ellis S; Balasegaram M; Boer MD; Rijal S; Strub-Wourgaft N; Alves F; Alvar J; Sharma B
PLoS Negl Trop Dis; 2017 May; 11(5):e0005635. PubMed ID: 28558062
[TBL] [Abstract][Full Text] [Related]
22. Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients.
Troya J; Casquero A; Refoyo E; Fernández-Guerrero ML; Górgolas M
Scand J Infect Dis; 2008; 40(1):78-80. PubMed ID: 17852921
[TBL] [Abstract][Full Text] [Related]
23. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
[TBL] [Abstract][Full Text] [Related]
24. Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations.
Monge-Maillo B; López-Vélez R
Clin Infect Dis; 2015 May; 60(9):1398-404. PubMed ID: 25601455
[TBL] [Abstract][Full Text] [Related]
25. Use of miltefosine in the treatment of visceral leishmaniasis in children at a tertiary care hospital of Karachi.
Humayun KN; Saleem T; Khalid U; Jehan F; Soofi S
J Pak Med Assoc; 2010 Jun; 60(6):489-91. PubMed ID: 20527651
[TBL] [Abstract][Full Text] [Related]
26. Inadequacy of 12-Week Miltefosine Treatment for Indian Post-Kala-Azar Dermal Leishmaniasis.
Ghosh S; Das NK; Mukherjee S; Mukhopadhyay D; Barbhuiya JN; Hazra A; Chatterjee M
Am J Trop Med Hyg; 2015 Oct; 93(4):767-9. PubMed ID: 26175030
[TBL] [Abstract][Full Text] [Related]
27. The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.
Abongomera C; Diro E; de Lima Pereira A; Buyze J; Stille K; Ahmed F; van Griensven J; Ritmeijer K
PLoS Negl Trop Dis; 2018 May; 12(5):e0006527. PubMed ID: 29799869
[TBL] [Abstract][Full Text] [Related]
28. Miltefosine in children with visceral leishmaniasis: a prospective, multicentric, cross-sectional study.
Singh UK; Prasad R; Mishra OP; Jayswal BP
Indian J Pediatr; 2006 Dec; 73(12):1077-80. PubMed ID: 17202633
[TBL] [Abstract][Full Text] [Related]
29. Treatment of leishmaniasis with miltefosine: 2008 status.
Berman JJ
Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114
[TBL] [Abstract][Full Text] [Related]
30. [Treatment of visceral leishmaniasis: efficacy and limits of miltefosine].
Gangneux JP; Marty P
Sante; 2001; 11(4):257-8. PubMed ID: 11861203
[No Abstract] [Full Text] [Related]
31. Serial use of pentamidine and miltefosine for treating Leishmania infantum-HIV coinfection.
Faucher JF; Morquin D; Reynes J; Chirouze C; Hoen B; Le Moing V
Parasitol Int; 2016 Oct; 65(5 Pt A):444-6. PubMed ID: 27353022
[TBL] [Abstract][Full Text] [Related]
32. One-year follow-up of immunocompetent male patients treated with miltefosine for primary visceral leishmaniasis in Bihar, India.
Burza S; Nabi E; Mahajan R; Mitra G; Lima MA
Clin Infect Dis; 2013 Nov; 57(9):1363-4. PubMed ID: 23943824
[No Abstract] [Full Text] [Related]
33. Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome.
Hendrickx S; Eberhardt E; Mondelaers A; Rijal S; Bhattarai NR; Dujardin JC; Delputte P; Cos P; Maes L
J Antimicrob Chemother; 2015 Nov; 70(11):3023-6. PubMed ID: 26253089
[TBL] [Abstract][Full Text] [Related]
34. Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection.
Kip AE; Rosing H; Hillebrand MJ; Blesson S; Mengesha B; Diro E; Hailu A; Schellens JH; Beijnen JH; Dorlo TP
Antimicrob Agents Chemother; 2016 Apr; 60(4):2081-9. PubMed ID: 26787691
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial.
Mbui J; Olobo J; Omollo R; Solomos A; Kip AE; Kirigi G; Sagaki P; Kimutai R; Were L; Omollo T; Egondi TW; Wasunna M; Alvar J; Dorlo TPC; Alves F
Clin Infect Dis; 2019 Apr; 68(9):1530-1538. PubMed ID: 30188978
[TBL] [Abstract][Full Text] [Related]
36. Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient.
Pandey BD; Pandey K; Kaneko O; Yanagi T; Hirayama K
Am J Trop Med Hyg; 2009 Apr; 80(4):580-2. PubMed ID: 19346379
[TBL] [Abstract][Full Text] [Related]
37. Drug resistance in Indian visceral leishmaniasis.
Sundar S
Trop Med Int Health; 2001 Nov; 6(11):849-54. PubMed ID: 11703838
[TBL] [Abstract][Full Text] [Related]
38. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
Sundar S; Rai M; Chakravarty J; Agarwal D; Agrawal N; Vaillant M; Olliaro P; Murray HW
Clin Infect Dis; 2008 Oct; 47(8):1000-6. PubMed ID: 18781879
[TBL] [Abstract][Full Text] [Related]
39. Multiple relapses of visceral leishmaniasis in a patient with HIV in India: a treatment challenge.
Patole S; Burza S; Varghese GM
Int J Infect Dis; 2014 Aug; 25():204-6. PubMed ID: 24927662
[TBL] [Abstract][Full Text] [Related]
40. Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients.
Marques N; Sá R; Coelho F; Oliveira J; Saraiva Da Cunha J; Meliço-Silvestre A
Scand J Infect Dis; 2008; 40(6-7):523-6. PubMed ID: 18584541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
